top of page
    • Aug 13

Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production

She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that Avidity has the strongest delivery in the field.



Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page